Roche - Roche's Avastin (bevacizumab) plus chemotherapy receives FDA approval for platinum-sensitive recurrent ovarian cancer
FOLFIRI plus cetuximab or bevacizumab for advanced colorectal cancer: final survival and per-protocol analysis of FIRE-3, a randomised clinical trial | British Journal of Cancer
Impact of primary tumor location in patients with RAS wild-type metastatic colon cancer treated with first-line chemotherapy plus anti-EGFR or anti-VEGF monoclonal antibodies: a retrospective multicenter study
Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE). | Semantic Scholar
Bevacizumab in First-line Therapy of Metastatic Colorectal Cancer: A Retrospective Comparison of FOLFIRI and XELIRI | Anticancer Research
PLOS ONE: Partnering bevacizumab with irinotecan as first line-therapy of metastatic colorectal cancer improves progression free survival-A retrospective analysis
Impact of primary tumour location on efficacy of bevacizumab plus chemotherapy in metastatic colorectal cancer | British Journal of Cancer
FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study - The
Continuation or reintroduction of bevacizumab beyond progression to first-line therapy in metastatic colorectal cancer: final results of the randomized BEBYP trial - Annals of Oncology
Combination therapy of bevacizumab with either S-1 and irinotecan or mFOLFOX6/CapeOX as first-line treatment of metastatic colorectal cancer (TRICOLORE): Exploratory analysis of RAS status and primary tumour location in a randomised, open-label,
Combination chemotherapy with TAS‑102 plus bevacizumab in salvage‑line treatment of metastatic colorectal cancer: A single‑center, retrospective study examining the prognostic value of the modified Glasgow Prognostic Score in salvage‑line therapy of ...
PLOS ONE: Partnering bevacizumab with irinotecan as first line-therapy of metastatic colorectal cancer improves progression free survival-A retrospective analysis
Results From the CALGB/SWOG 80405 and FIRE-3 (AIO KRK-0306) Studies In All RAS Wild Type Population | ESMO
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer | NEJM
Overall survival with chemotherapy involving bevacizumab in mcrc... | Download Scientific Diagram
Chemotherapy, Bevacizumab, and Cetuximab in Metastatic Colorectal Cancer | NEJM
Primary tumor location and survival in colorectal cancer: A retrospective cohort study
FOLFIRI plus bevacizumab as second-line therapy in patients with metastatic colorectal cancer after first-line bevacizumab plus oxaliplatin-based therapy: the randomized phase III EAGLE study† - Annals of Oncology
Overall survival for colorectal cancer patients treated with FOLFIRI®... | Download Scientific Diagram
Retrospective evaluation of FOLFIRI3 alone or in combination with bevacizumab or aflibercept in metastatic colorectal cancer
Frontiers | Doubling the Dose of Bevacizumab Beyond Progression in Metastatic Colorectal Cancer–the Experience of a Tertiary Cancer Center | Pharmacology
Bevacizumab in First-line Therapy of Metastatic Colorectal Cancer: A Retrospective Comparison of FOLFIRI and XELIRI | Anticancer Research
![PDF] Therapy for metastatic colorectal cancer. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/8f71e8746365052e23ebf2293b9b25e7d432b2f6/2-Figure1-1.png "PDF] Therapy for metastatic colorectal cancer. | Semantic Scholar")
PDF] Therapy for metastatic colorectal cancer. | Semantic Scholar
Efficacy and Safety of Bevacizumab Combined With First-Line Chemotherapy in Elderly (≥75 Years) Patients With Metastatic Colorectal Cancer: A Real-World Study - Clinical Colorectal Cancer
Kaplan-Meier curves comparing overall survival for combination... | Download Scientific Diagram
